|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/20 | (2006.01) |
| A61K 38/2086 | (2013.01) | ||
| G01N 33/50 | (2006.01) | ||
| G01N 33/6869 | (2013.01) | ||
| G01N2333/5443 | (2013.01) | ||
| G01N2333/7155 | (2013.01) |
| (11) | Number of the document | 4188418 |
| (13) | Kind of document | T |
| (96) | European patent application number | 21762839.5 |
| Date of filing the European patent application | 2021-07-21 | |
| (97) | Date of publication of the European application | 2023-06-07 |
| (45) | Date of publication and mention of the grant of the patent | 2025-04-02 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2021/042531 |
| Date | 2021-07-21 |
| (87) | Number | WO 2022/031440 |
| Date | 2022-02-10 |
| (30) | Number | Date | Country code |
| 202063060256 P | 2020-08-03 | US |
| (72) |
TANAKA, Shiho , US
NIAZI, Kayvan , US
|
| (73) |
Nantcell, Inc. ,
9920 Jefferson Boulevard, Culver City, California 90232,
US
|
| (54) | DRUG-SPECIFIC PHARMACOKINETIC ASSAY FOR IL-15 SUPERAGONIST |
| DRUG-SPECIFIC PHARMACOKINETIC ASSAY FOR IL-15 SUPERAGONIST |